pEB1N-mScarlet-LZ-LOV2
(Plasmid
#197419)
-
PurposeMammalian expression of the mScarlet-tagged N-terminal half of photo-inactivated π-EB1
-
Depositing Lab
-
Depositing OrganizationUniversity of California, San Francisco (UCSF)
Located in United States of America -
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 197419 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 | |
| DNA | 197419-D50 | 50 μg of DNA in Tris buffer | $495 | ||
| DNA | 197419-D100 | 100 μg of DNA in Tris buffer | $585 | ||
Backbone
-
Vector backbonepEGFP-C1
-
Backbone manufacturerClontech
- Backbone size w/o insert (bp) 3941
- Total vector size (bp) 5786
-
Modifications to backboneremoved EGFP
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameMAPRE1
-
Alt nameEB1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)1845
-
MutationEB1 aa 1-185; resistant to EB1 shRNA#3 (Addgene #37927)
-
GenBank IDNM_012325.2
-
Entrez GeneMAPRE1 (a.k.a. EB1)
-
Tags
/ Fusion Proteins
- GCN4 leucine zipper (C terminal on insert)
- mScarlet-I (C terminal on insert)
- A. sativa phototropin 1 LOV2 domain (C terminal on insert)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer CMV forward
- 3′ sequencing primer SV40 reverse
- (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byEB1 from L. Cassimeris (Addgene #17234) LOV2 from Klaus Hahn (Addgene #22027)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
LOV2 domain starts with LAAA reported to stabilize Jα helix docking (Strickland et al. PMID: 22388287).
Please visit https://www.biorxiv.org/content/10.1101/2022.09.22.509085v1 for bioRxiv preprint.
DNA (Catalog # 197419-D50)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 50 μg
- Concentration 1 μg/μL
- Pricing $495 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
DNA (Catalog # 197419-D100)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 100 μg
- Concentration 1 μg/μL
- Pricing $585 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pEB1N-mScarlet-LZ-LOV2 was a gift from Torsten Wittmann (Addgene plasmid # 197419 ; http://n2t.net/addgene:197419 ; RRID:Addgene_197419) -
For your References section:
Growth cone advance requires EB1 as revealed by genomic replacement with a light-sensitive variant. Dema A, Charafeddine R, Rahgozar S, van Haren J, Wittmann T. Elife. 2023 Jan 30;12:e84143. doi: 10.7554/eLife.84143. 10.7554/eLife.84143 PubMed 36715499